These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence. Daungsupawong H; Wiwanitkit V Semergen; 2024; 50(4):102132. PubMed ID: 38295632 [No Abstract] [Full Text] [Related]
37. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease. Melmed GY; Botwin GJ; Sobhani K; Li D; Prostko J; Figueiredo J; Cheng S; Braun J; McGovern DPB Ann Intern Med; 2021 Dec; 174(12):1768-1770. PubMed ID: 34633830 [No Abstract] [Full Text] [Related]
38. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867 [No Abstract] [Full Text] [Related]
39. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157 [TBL] [Abstract][Full Text] [Related]
40. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]